Opsahl EM, Akslen LA, Schlichting E, Aas T, Brauckhoff K, Hagen AI et al. Trends in Diagnostics, Surgical Treatment, and Prognostic Factors for Outcomes in Medullary Thyroid Carcinoma in Norway: A Nationwide Population-Based Study. Eur Thyroid J 8: 31-40, 2019.

Article  CAS  PubMed  Google Scholar 

Randle RW, Balentine CJ, Leverson GE, Havlena JA, Sippel RS, Schneider DFet al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery 161: 137-146, 2017.

Article  PubMed  Google Scholar 

Barletta JA, Nose V, Sadow PM Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations. Endocr Pathol 32: 35-43, 2021.

Article  PubMed  PubMed Central  Google Scholar 

Wells SA, Jr., Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25: 567-610, 2015.

Article  PubMed  PubMed Central  Google Scholar 

Elisei R, Tacito A, Ramone T, Ciampi R, Bottici V, Cappagli V et al. Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations. Genes (Basel) 10, 2019.

Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 98: E364-369, 2013.

Article  CAS  PubMed  Google Scholar 

Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab 97: E2031-2035, 2012.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 23: 50-57, 2013.

Article  CAS  PubMed  Google Scholar 

Moura MM, Cavaco BM, Pinto AE, Leite V High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 96: E863-868, 2011.

Article  CAS  PubMed  Google Scholar 

Reagh J, Bullock M, Andrici J, Turchini J, Sioson L, Clarkson A et al. NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2. Am J Surg Pathol 41: 75-81, 2017.

Article  PubMed  Google Scholar 

Jayakody S, Reagh J, Bullock M, Aniss A, Clifton-Bligh R, Learoyd D et al. Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease. World J Surg 42: 1432-1439, 2018.

Article  CAS  PubMed  Google Scholar 

Censi S, Galuppini F, Clausi C, Battheu F, Manso J, Piva I et al. Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma. Thyroid 34: 177-185, 2024.

Article  CAS  PubMed  Google Scholar 

Xu B, Viswanathan K, Ahadi MS, Ahmadi S, Alzumaili B, Bani MA et al. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study. Thyroid 34: 167-176, 2024.

Article  CAS  PubMed  Google Scholar 

Correa FA, Farias EC, Castroneves LA, Lourenco DM, Jr., Hoff AO Quality of Life and Coping in Multiple Endocrine Neoplasia Type 2. J Endocr Soc 3: 1167-1174, 2019.

Article  PubMed  PubMed Central  Google Scholar 

Johnson DN, Sadow PM Exploration of BRAFV600E as a diagnostic adjuvant in the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Hum Pathol 82: 32-38, 2018.

Article  CAS  PubMed  Google Scholar 

Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS et al. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol 46: 1101-1110, 2015.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen L, Voronovich Z, Clark K, Hands I, Mannas J, Walsh M et al. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro Oncol 16: 1478-1483, 2014.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alzumaili BA, Fisch AS, Faquin WC, Nose V, Randolph GW, Sadow PM Detection of RAS p.Q61R by Immunohistochemistry in Practice: A Clinicopathologic Study of 217 Thyroid Nodules with Molecular Correlates. Endocr Pathol, 2024.

Massi D, Simi L, Sensi E, Baroni G, Xue G, Scatena C et al. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma. Mod Pathol 28: 487-497, 2015.

Article  CAS  PubMed  Google Scholar 

Oishi N, Kondo T, Vuong HG, Nakazawa T, Mochizuki K, Kasai Ket al. Immunohistochemical detection of NRAS(Q61R) protein in follicular-patterned thyroid tumors. Hum Pathol 53: 51-57, 2016.

Article  CAS  PubMed  Google Scholar 

Saliba M, Katabi N, Dogan S, Xu B, Ghossein RA NRAS Q61R immunohistochemical staining in thyroid pathology: sensitivity, specificity and utility. Histopathology 79: 650-660, 2021.

Article  PubMed  PubMed Central  Google Scholar 

Turchini J, Andrici J, Sioson L, Clarkson A, Watson N, Toon CW et al. NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRASQ61R or KRASQ61R Mutation in Colorectal Carcinoma. Appl Immunohistochem Mol Morphol 25: 475-480, 2017.

Article  CAS  PubMed  Google Scholar 

Viswanathan K, Behrman DB, Lubin DJ Grading medullary thyroid carcinoma on fine-needle aspiration cytology specimens with the International Medullary Thyroid Carcinoma Grading System: A cytologic-histologic correlation. Cancer Cytopathol 132: 224-232, 2024.

Article  CAS  PubMed  Google Scholar 

Hartsough E, Mino-Kenudson M, Lennerz JK, Dias-Santagata D, Hoang MP Clinical Next-Generation Sequencing Panels Reveal Molecular Differences Between Merkel Cell Polyomavirus-Negative Merkel Cell Carcinomas and Neuroendocrine Carcinomas. Am J Clin Pathol 159: 395-406, 2023.

Article  CAS  PubMed  Google Scholar 

Elisei R, Ciampi R, Matrone A, Prete A, Gambale C, Ramone T et al. Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib. J Clin Endocrinol Metab 107: 2195-2202, 2022.

Article  PubMed  Google Scholar 

Baumgartner-Parzer SM, Lang R, Wagner L, Heinze G, Niederle B, Kaserer K et al. Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab 90: 6232-6236, 2005.

Article  CAS  PubMed  Google Scholar 

Bongarzone I, Vigano E, Alberti L, Mondellini P, Uggeri M, Pasini B et al. The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein. Oncogene 18: 4833-4838, 1999.

Article  CAS  PubMed  Google Scholar 

Kim M, Jeon S, Jung CK Preoperative Risk Stratification of Follicular-patterned Thyroid Lesions on Core Needle Biopsy by Histologic Subtyping and RAS Variant-specific Immunohistochemistry. Endocr Pathol 34: 247-256, 2023.

Article  CAS  PubMed  Google Scholar 

Kakavand H, Walker E, Lum T, Wilmott JS, Selinger CI, Smith E et al. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Histopathology 69: 680-686, 2016.

Article  PubMed  Google Scholar 

Nakaguro M, Tanigawa M, Hirai H, Yamamoto Y, Urano M, Takahashi RH et al. The Diagnostic Utility of RAS Q61R Mutation-specific Immunohistochemistry in Epithelial-Myoepithelial Carcinoma. Am J Surg Pathol 45: 885-894, 2021.

Article  PubMed  PubMed Central  Google Scholar